Protembis GmbH has successfully completed a €30 million Series B financing round to support the initiation of its PROTEMBO Investigational Device Exemption Pivotal Trial, highlighting strong investor confidence in its innovative cerebral protection technology.

Target Information

Protembis GmbH (Protembis) is an emerging cardiovascular medical device company based in Aachen, Germany. The company specializes in the development of innovative solutions to protect patients from brain injuries during left-sided heart procedures. Protembis is particularly known for its ProtEmbo® Cerebral Protection System, an intra-aortic filter device designed to prevent embolic materials from affecting the brain during transcatheter aortic valve replacement (TAVR). This device is designed to be low-profile and non-thrombogenic, ensuring optimal placement and stability.

The ProtEmbo System is currently undergoing clinical trials aimed at demonstrating its efficacy and safety. Protembis aims to enhance patient quality of life and reduce healthcare costs associated with brain injuries, positioning itself as a key player in the rapidly evolving cardiovascular medical device sector.

Industry Overview

The cardiovascular medical device industry has shown considerable growth, with increasing demand for innovative solutions that enhance procedural safety and effectiveness. In Germany, a country known for its advanced healthcare system and strong emphasis on m